Is Brilinta The Treatment To Keep AstraZeneca’s Lifeblood Flowing?
Executive Summary
The company outlined plans to jumpstart growth of the anti-platelet drug Brilinta, including a 100% increase in marketing investment, increased rebates for payers and the addition of 200 nurse educators who will focus on the hospital discharge space.
You may also be interested in...
AstraZeneca's Hudson Optimistic On Return To Growth In 2017
US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.
AstraZeneca’s Brilinta Gives Brilliant Sales Performance
AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly in the crucial US market.
Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.